Ranbaxy receives nod for Tamsulosin Hydrochloride capsules in Canada

MUMBAI: Ranbaxy Laboratories has received approval to manufacture and market Tamsulosin Hydrochloride capsules in 0.4 mg strength from Health Canada, Therapeutic Products Directorate. This product has proven to be bio-equivalent to Flomax capsules which is indicated for the treatment of benign prostatic hyperplasia. The total market for both generic and brand Tamsulosin Hydrochloride capsules in Canada is Canadian $22 million.

“This formulation was fully developed within out parent company Ranbaxy Laboratories. This is the fourth product to be added to our portfolio in 2007,” said Paul Drake, president, Ranbaxy Pharmaceuticals Canada Inc. Ranbaxy Pharmaceuticals-Canada Inc. is a wholly owned subsidiary of the company and is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.